213 related articles for article (PubMed ID: 29463527)
1. A New Marker of Echinocandin Activity in an
Meletiadis J; Siopi M; Tsakris A; Mouton JW; Pournaras S
Antimicrob Agents Chemother; 2018 May; 62(5):. PubMed ID: 29463527
[TBL] [Abstract][Full Text] [Related]
2. Comparative Pharmacodynamics of Echinocandins against Aspergillus fumigatus Using an
Siopi M; Perlin DS; Arendrup MC; Pournaras S; Meletiadis J
Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33495222
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
[TBL] [Abstract][Full Text] [Related]
4. Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.
Siopi M; Siafakas N; Vourli S; Mouton JW; Zerva L; Meletiadis J
J Antimicrob Chemother; 2016 Nov; 71(11):3135-3147. PubMed ID: 27494912
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia.
Antachopoulos C; Meletiadis J; Sein T; Roilides E; Walsh TJ
Antimicrob Agents Chemother; 2008 Jan; 52(1):321-8. PubMed ID: 17938191
[TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model.
Meletiadis J; Al-Saigh R; Velegraki A; Walsh TJ; Roilides E; Zerva L
Antimicrob Agents Chemother; 2012 Jan; 56(1):403-10. PubMed ID: 22064546
[TBL] [Abstract][Full Text] [Related]
7. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
8. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates.
Pfaller MA; Messer SA; Rhomberg PR; Jones RN; Castanheira M
J Antimicrob Chemother; 2016 Oct; 71(10):2868-73. PubMed ID: 27287236
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.
Arendrup MC; Garcia-Effron G; Buzina W; Mortensen KL; Reiter N; Lundin C; Jensen HE; Lass-Flörl C; Perlin DS; Bruun B
Antimicrob Agents Chemother; 2009 Mar; 53(3):1185-93. PubMed ID: 19104024
[TBL] [Abstract][Full Text] [Related]
10. Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY 2014 Antifungal Surveillance Program.
Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 28052853
[TBL] [Abstract][Full Text] [Related]
11. Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.
Siopi M; Mavridou E; Mouton JW; Verweij PE; Zerva L; Meletiadis J
J Antimicrob Chemother; 2014 Jun; 69(6):1611-9. PubMed ID: 24550381
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus.
Lewis RE; Liao G; Hou J; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2011 Jun; 66(6):1324-31. PubMed ID: 21486855
[TBL] [Abstract][Full Text] [Related]
13. In vitro pharmacokinetic/pharmacodynamic modeling of voriconazole activity against Aspergillus species in a new in vitro dynamic model.
Al-Saigh R; Elefanti A; Velegraki A; Zerva L; Meletiadis J
Antimicrob Agents Chemother; 2012 Oct; 56(10):5321-7. PubMed ID: 22869563
[TBL] [Abstract][Full Text] [Related]
14. Caspofungin: antifungal activity in vitro, pharmacokinetics, and effects on fungal load and animal survival in neutropenic rats with invasive pulmonary aspergillosis.
van Vianen W; de Marie S; ten Kate MT; Mathot RA; Bakker-Woudenberg IA
J Antimicrob Chemother; 2006 Apr; 57(4):732-40. PubMed ID: 16464895
[TBL] [Abstract][Full Text] [Related]
15. Combination of voriconazole and anidulafungin for treatment of triazole-resistant aspergillus fumigatus in an in vitro model of invasive pulmonary aspergillosis.
Jeans AR; Howard SJ; Al-Nakeeb Z; Goodwin J; Gregson L; Warn PA; Hope WW
Antimicrob Agents Chemother; 2012 Oct; 56(10):5180-5. PubMed ID: 22825124
[TBL] [Abstract][Full Text] [Related]
16. Comparative Evaluation of Sensititre YeastOne and CLSI M38-A2 Reference Method for Antifungal Susceptibility Testing of Aspergillus spp. against Echinocandins.
Siopi M; Pournaras S; Meletiadis J
J Clin Microbiol; 2017 Jun; 55(6):1714-1719. PubMed ID: 28330883
[TBL] [Abstract][Full Text] [Related]
17. Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.
Satish S; Jiménez-Ortigosa C; Zhao Y; Lee MH; Dolgov E; Krüger T; Park S; Denning DW; Kniemeyer O; Brakhage AA; Perlin DS
mBio; 2019 Jun; 10(3):. PubMed ID: 31164462
[No Abstract] [Full Text] [Related]
18. Effect of protein binding on the activity of voriconazole alone or combined with anidulafungin against Aspergillus spp. using a time-kill methodology.
Cafini F; Sevillano D; Alou L; Gómez-Aguado F; Corcuera MT; González N; Guinea J; Prieto J
Rev Esp Quimioter; 2012 Mar; 25(1):47-55. PubMed ID: 22488542
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and pharmacodynamics of voriconazole combined with anidulafungin in azole-resistant invasive aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Rijs AJ; Verweij PE; Mouton JW
J Antimicrob Chemother; 2013 Feb; 68(2):385-93. PubMed ID: 23129729
[TBL] [Abstract][Full Text] [Related]
20. APX001 Pharmacokinetic/Pharmacodynamic Target Determination against
Zhao M; Lepak AJ; Marchillo K; Vanhecker J; Sanchez H; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
